人乳头瘤病毒疫苗的临床研究进展

Efficacy of Human Papillomavirus Vaccines: A Systematic Quantitative Review[J] . Lidia Rosi Medeiros,Daniela Dornelles Rosa,Maria Inês da Rosa,Mary Clarisse Bozzetti,Roselaine Ruviaro Zanini.International Journal of Gynecological Cancer . 2009 (7)

Immunogenicity, Reactogenicity, and Safety of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women: Interim Analysis of a Phase II, Double-blind, Randomized Controlled Trial at Month 7[J] . Ryo Konno,Kurt O. Dobbelaere,Olivier O. Godeaux,Shinobu Tamura,Hiroyuki Yoshikawa.International Journal of Gynecological Cancer . 2009 (5)

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus （types 6, 11, 16, 18） recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial[J] . The Lancet . 2009 (9679)

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses[J] . Marie-Pierre David,Koen Van Herck,Karin Hardt,Fabian Tibaldi,Gary Dubin,Dominique Descamps,Pierre Van Damme.Gynecologic Oncology . 2009 (3)

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention[J] . David Jenkins.Gynecologic Oncology . 2008 (3)

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial[J] . Jorma Paavonen,David Jenkins,F Xavier Bosch,Paulo Naud,Jorge Salmerón,Cosette M Wheeler,Song-Nan Chow,Dan L Apter,Henry C Kitchener,Xavier Castellsague,Newton S de Carvalho,S Rachel Skinner,Diane M Harper,James A Hedrick,Unnop Jaisamrarn,Genara AM Limson,Marc Dion

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial[J] . Diane M Harper,Eduardo L Franco,Cosette M Wheeler,Anna-Barbara Moscicki,Barbara Romanowski,Cecilia M Roteli-Martins,David Jenkins,Anne Schuind,Sue Ann Costa Clemens,Gary Dubin.The Lancet . 2006 (9518)

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18[J] . Luisa L. Villa,Kevin A. Ault,Anna R. Giuliano,Ronaldo L.R. Costa,Carlos A. Petta,Rosires P. Andrade,Darron R. Brown,Alex Ferenczy,Diane M. Harper,Laura A. Koutsky,Robert J. Kurman,Matti Lehtinen,Christian Malm,Sven-Eric Olsson,Brigitte M. Ronnett,Finn Egil Skjeldestad,Margareta Steinwall,Mark H. Stoler,Cosette M. Wheeler,Frank J. Taddeo,Jimmy Yu,Lisa Lupinacci,Radha Railkar,Roc

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial[J] . Diane M Harper,Eduardo L Franco,Cosette Wheeler,Daron G Ferris,David Jenkins,Anne Schuind,Toufik Zahaf,Bruce Innis,Paulo Naud,Newton S De Carvalho,Cecilia M Roteli-Martins,Julio Teixeira,Mark M Blatter,Abner P Korn,Wim Quint,Gary Dubin.The Lancet . 2004 (9447)

Efficacy of Human Papillomavirus Vaccines: A Systematic Quantitative Review[J] . Lidia Rosi Medeiros,Daniela Dornelles Rosa,Maria Inês da Rosa,Mary Clarisse Bozzetti,Roselaine Ruviaro Zanini.International Journal of Gynecological Cancer . 2009 (7)

Immunogenicity, Reactogenicity, and Safety of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women: Interim Analysis of a Phase II, Double-blind, Randomized Controlled Trial at Month 7[J] . Ryo Konno,Kurt O. Dobbelaere,Olivier O. Godeaux,Shinobu Tamura,Hiroyuki Yoshikawa.International Journal of Gynecological Cancer . 2009 (5)

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus （types 6, 11, 16, 18） recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial[J] . The Lancet . 2009 (9679)

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses[J] . Marie-Pierre David,Koen Van Herck,Karin Hardt,Fabian Tibaldi,Gary Dubin,Dominique Descamps,Pierre Van Damme.Gynecologic Oncology . 2009 (3)

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention[J] . David Jenkins.Gynecologic Oncology . 2008 (3)

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial[J] . Jorma Paavonen,David Jenkins,F Xavier Bosch,Paulo Naud,Jorge Salmerón,Cosette M Wheeler,Song-Nan Chow,Dan L Apter,Henry C Kitchener,Xavier Castellsague,Newton S de Carvalho,S Rachel Skinner,Diane M Harper,James A Hedrick,Unnop Jaisamrarn,Genara AM Limson,Marc Dion

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial[J] . Diane M Harper,Eduardo L Franco,Cosette M Wheeler,Anna-Barbara Moscicki,Barbara Romanowski,Cecilia M Roteli-Martins,David Jenkins,Anne Schuind,Sue Ann Costa Clemens,Gary Dubin.The Lancet . 2006 (9518)

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18[J] . Luisa L. Villa,Kevin A. Ault,Anna R. Giuliano,Ronaldo L.R. Costa,Carlos A. Petta,Rosires P. Andrade,Darron R. Brown,Alex Ferenczy,Diane M. Harper,Laura A. Koutsky,Robert J. Kurman,Matti Lehtinen,Christian Malm,Sven-Eric Olsson,Brigitte M. Ronnett,Finn Egil Skjeldestad,Margareta Steinwall,Mark H. Stoler,Cosette M. Wheeler,Frank J. Taddeo,Jimmy Yu,Lisa Lupinacci,Radha Railkar,Roc

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial[J] . Diane M Harper,Eduardo L Franco,Cosette Wheeler,Daron G Ferris,David Jenkins,Anne Schuind,Toufik Zahaf,Bruce Innis,Paulo Naud,Newton S De Carvalho,Cecilia M Roteli-Martins,Julio Teixeira,Mark M Blatter,Abner P Korn,Wim Quint,Gary Dubin.The Lancet . 2004 (9447)